Given the frequency of PTEN loss in PC and the effects its loss may have in promoting both tumor progression and TME immunosuppression, targeting the PI3K-AKT pathway in mid stage disease combined with immune checkpoint inhibition may provide enhanced therapeutic benefits. The gene discussed is PTEN; the disease is pachyonychia congenita.